The core strategy of Adalvo’s portfolio is innovation and differentiation, which allows us to make unique products available in the market, and supports our partners to target unmet medical needs.
In this respect, we are delighted to share an update on the addition of several new oral solutions, to our portfolio offerings, with our intention of supporting our partners in enhancing their value-added portfolio.
Our oral-solution products include:
- Methotrexate 2mg/5ml $ 304 Mio.
- Topiramate 10mg/ml and 20mg/ml 280ml $ 1 bi.
- Memantine Hydrochloride 10mg/ml $ 653 Mio.
- Ramipril 2.5mg/5ml $ 638 Mio.
- Quetiapine 20mg/ml $ 1.4 bi.
- Lisdexamfetamine Oral Solution 10mg /ml $ 4 bi
*Global market size in 2021, according to IQVIA
The products will be supplied from an European facility, whereby our partners have deep knowledge and experience with these specific forms, ensuring a lean and sustainable supply chain with competitive COGs.
With these new additions, we will continue to pursue our purpose of being the key partner for Companies that strive for innovative solutions and want to impact the market with differentiated products.
Disclaimer: products which are subject to patent protection are currently not offered or made available in countries where patents are in force.